Study Description
This study is a prospective, open-label, multi-center, non-comparative, observational study to assess safety and effectiveness of Asciminib in the real-world clinical setting in Korean Chronic myeloid leukemia (CML) patients.
Interventions
Asciminib
Eligibility Criteria
Inclusion criteria
Adult patients diagnosed with Ph+ CP-CML and currently receiving or going to receive Scemblix® treatment according to locally approval label
Patients who are willing to provide written informed consent prior to study enrollment
Exclusion criteria
Patients with contraindication according to locally approved label of Scemblix®
Patients who receive or are going to receive any investigational medicine during the observation period
Study Location
Novartis Investigative Site
Recruiting
Seoul,03722,Korea, Republic of
Novartis Investigative Site
Recruiting
Seoul,Seocho Gu,06591,Korea, Republic of
Novartis Investigative Site
Recruiting
Taegu,41944,Korea, Republic of
Novartis Investigative Site
Recruiting
Uijeongbu si,Gyeonggi Do,11759,Korea, Republic of
Novartis Investigative Site
Recruiting
Wonju-si,Gangwon-do,26426,Korea, Republic of
Novartis Investigative Site
Recruiting
Pusan,614 735,Korea, Republic of
Novartis Investigative Site
Recruiting
Seoul,03080,Korea, Republic of
Worldwide Contacts
If the location of your choosing does not feature any contact detail, please reach out using the information below.